| Objective: To evaluate the immune phenotypic characterization ofmalignant lymphoid leukemia, and to analyze the treatment of reactive.Methods: Immunopheotypes were examined using indirect immunofluoresence methods in53lymphoma/leukemia, including ALL33cases,(B-ALL23cases, T-ALL5cases, MAL5cases), CLL11cases, LMCL8casesand NK-CLL1cases. The immune phenotypic characterizations of all the caseswere analyzed by FCM, and all cases were treated with combinedchemotherapy. VP, VDLP, VDCLP regime were used to treat ALL; leukeran/prednisone、FCP、FCM regime were used to treat CLL; CHOP、COP or ALLregime were used to treat lymphoma/leukemia; observe the effect of thesetreatments. Then analyzed the difference of CR rate between lymphoid antigenpositive AML and lymphoid antigen negative AML, the difference of CR ratebetween myeloid antigen positive ALL and myeloid antigen negative ALL(Chisquare test. P<0.05was considered as significance).All the statisticalvariance was carried on via SPSS10.0in personal computer.Result:(1) All of the ALL cases, in33B-ALL cases, the positive incidencefrom high to low are CDl9, CD79a, HLA-DR, CD22, CD34, CD10and CD-20.They are95.65％,69.57%,60.87%,47.83%,47.82%,43.48%,34.78%. Theincidence of myeloid antigen CD13、CD33is high in5of23B-ALL cases, andthe incidence of lymphoid T-antigen CD3is low in1of23B-ALL cases. In5T-ALL cases, the positive incidence from high to low are CD7, cCD3, CD5andCD2. They are100%,100%,80%,40%. Myeloid antigen and lymphoidB-antigen cCD79a, CD19, CD13, CD33express in2of5MAL cases, myeloidantigen and lymphoid T-antigen MPO, cCD3express in1of5MAL cases,lymphoid B-antigen and lymphoid T-antigen cCD79a, CD7express in2of5 MAL cases. CD117doesn’t express in ALL.(2)10of11CLL cases are B-CLL,the incidence of CD19, CD20is highest, it is100%, the positive incidence ofCD5, CD23and CD79a is80%,60%and18.19%. The incidence of FMC-7isexpressed in3cases. The incidence of ZAP-70is negative in1case. Theincidence of CD13, CD11is expressed in2cases. The incidence of CD3,CD8, CD5, CD7is expressed in1case. The incidence of CDla、CDl4、CD34、CD57and HLA-DR is negative in all of11CLL cases.(3) In8LMCL cases,4cases are B lymphocytes, the positive incidence of CD19is73%, and thepositive incidence of CD20, CD79a, CD34, CD38is all50%;2cases are Tlymphocytes, they both express CD17, but one of them express CD33andCD13;2cases accompany with complex cerotype, and1of them express cCK.In1NK case, the incidence of CD3and CD56is positive，and CD57isnegative.(4) CR cases in23B-ALL is15, CR rate is65.22%. In these B-ALLcases, CR cases in11Pro-B-ALL is10, CR rate is90.9%; CR cases in8cALLis5, CR rate is62.5%; CR cases in4Pre-B-ALL is2, CR rate is50%. CRcases in5T-ALL is1, CR rate is20%. CR rate in B-ALL cases is higher thanT-ALL(65.22%VS20%, p＜0.01). CR rate in myeloid antigen positive ALL islower than in myeloid antigen negative ALL (28.57%(2/7)Vs76.19%(16/21),p<0.05). CR rate in CD34positive AL is no different from CD34negative AL(53.84%（7/13）Vs58.33%（7/12）, p＞0.05). CR rate in HLA-DR positive ALis no different from HLA-DR negative AL(50%（8/16）Vs58.33%（7/12）, p＞0.05). CR rate in CD10positive B-ALL is higher than CD10negativeB-ALL (80%（8/10）Vs56.85%（7/13）, p＜0.01).(5) CR cases in11CLL is5,CR rate is45.46%. CR rate in CD23positive CLL is no different from CD23negative CLL (50%（3/6）Vs40%（2/5）, p＞0.05). CR cases in8LMCL is3,CR rate is37.5%. The NK/T case is not cure.Conclusion:(1) We can select specific antigens to distinguish the sources of lymphoma/leukemia cells, for example, CDl9, CD79a, CD7, cCD3, CD5,CD10, CD34. CD19, CD20and CD5all express can be regarded as B-CLLcase. CD3, CD56and CD57are the antigens to distinguish the sources of NKand T lymphocyte.(2) The B-ALL CR rate is better than T-ALL; In ALL,lymphoid antigen is related with CR rate, it might predict a poor clinicaloutcome; There is little relationship between the express enhance of CD34,HLA-DR and prognosis; The clinical outcome of B-ALL which company withCD10express is better than B-ALL which company with CD10-; MAL has thedual characteristics of myeloid and lymphoid lineage, and has poor prognosis.(4) It is easy to reflect the heterogeneity of leukemic cells by immunophenotype．It is valuable to diagnose and phenotype leukemia, select treatmentregimens, judge prognosis and research the mechanism. |
PDF Full Text Request